The combination of ibrutinib and rituximab demonstrates activity in first‐line follicular lymphoma
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The combination of ibrutinib and rituximab demonstrates activity in first‐line follicular lymphoma
Authors
Keywords
-
Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 189, Issue 4, Pages 650-660
Publisher
Wiley
Online
2020-03-17
DOI
10.1111/bjh.16424
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy
- (2019) Emanuele Zucca et al. BLOOD
- Bendamustine plus Rituximab Versus R‐CHOP as First‐Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study
- (2018) Patrizia Mondello et al. ONCOLOGIST
- Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma
- (2018) Franck Morschhauser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
- (2017) Robert Marcus et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rituximab in the treatment of follicular lymphoma: the future of biosimilars in the evolving therapeutic landscape
- (2017) Janakiraman Subramanian et al. Cancer Management and Research
- Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103
- (2016) Chaitra S. Ujjani et al. BLOOD
- Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study
- (2014) I. W. Flinn et al. BLOOD
- Rituximab Extended Schedule or Re-Treatment Trial for Low–Tumor Burden Follicular Lymphoma: Eastern Cooperative Oncology Group Protocol E4402
- (2014) Brad S. Kahl et al. JOURNAL OF CLINICAL ONCOLOGY
- Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial
- (2014) Kirit M Ardeshna et al. LANCET ONCOLOGY
- Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial
- (2014) Nathan H Fowler et al. LANCET ONCOLOGY
- Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
- (2013) Mathias J Rummel et al. LANCET
- Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
- (2012) Ranjana H. Advani et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Factors in Follicular Lymphoma
- (2010) Thomas Relander et al. JOURNAL OF CLINICAL ONCOLOGY
- The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
- (2010) L. A. Honigberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Placebo-Controlled Phase III Trial of Patient-Specific Immunotherapy With Mitumprotimut-T and Granulocyte-Macrophage Colony-Stimulating Factor After Rituximab in Patients With Follicular Lymphoma
- (2009) Arnold Freedman et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study of R-CVP Compared With Cyclophosphamide, Vincristine, and Prednisone Alone in Patients With Previously Untreated Advanced Follicular Lymphoma
- (2008) Robert Marcus et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation